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Background: In 2001, the WHO Antenatal Care Trial (WHOACT) concluded that an antenatal care package of
evidence-based screening, therapeutic interventions and education across four antenatal visits for low-risk women
was not inferior to standard antenatal care and may reduce cost. However, an updated Cochrane review in 2010
identified an increased risk of perinatal mortality of borderline statistical significance in three cluster-randomized
trials (including the WHOACT) in developing countries. We conducted a secondary analysis of the WHOACT data to
determine the relationship between the reduced visits, goal-oriented antenatal care package and perinatal
mortality.
Methods: Exploratory analyses were conducted to assess the effect of baseline risk and timing of perinatal death.
Women were stratified by baseline risk to assess differences between intervention and control groups. We used
linear modeling and Poisson regression to determine the relative risk of fetal death, neonatal death and perinatal
mortality by gestational age.
Results: 12,568 women attended the 27 intervention clinics and 11,958 women attended the 26 control clinics.
6,160 women were high risk and 18,365 women were low risk. There were 161 fetal deaths (1.4%) in the
intervention group compared to 119 fetal deaths in the control group (1.1%) with an increased overall adjusted
relative risk of fetal death (Adjusted RR 1.27; 95% CI 1.03, 1.58). This was attributable to an increased relative risk of
fetal death between 32 and 36 weeks of gestation (Adjusted RR 2.24; 95% CI 1.42, 3.53) which was statistically
significant for high and low risk groups.
Conclusion: It is plausible the increased risk of fetal death between 32 and 36 weeks gestation could be due to
reduced number of visits, however heterogeneity in study populations or differences in quality of care and timing
of visits could also be playing a role. Monitoring maternal, fetal and neonatal outcomes when implementing
antenatal care protocols is essential. Implementing reduced visit antenatal care packages demands careful
monitoring of maternal and perinatal outcomes, especially fetal death.
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Many attempts have been made to rationalize the
content, frequency and implementation of antenatal care
in response to new evidence and technologies [1-4] and
systematic reviews have examined the effectiveness of
individual components of antenatal care programs [5-9].
Evidence-based, validated and safe antenatal care pack-
ages recommending fewer visits for low-risk women
have large implications for developing countries, where
resources are scarce and antenatal care poses both finan-
cial and logistical challenges to patients and health
systems.
In 2001, Villar and colleagues published the findings
of the WHO Antenatal Care Trial (hereafter referred to
as the WHO ANC Trial), a multi-center, cluster-
randomized trial of an evidence based, reduced visit pack-
age of antenatal care in Thailand, Cuba, Saudi Arabia and
Argentina [10]. The trial found that a reduction in the
number of visits and application of goal oriented, effective
antenatal activities was not inferior to standard antenatal
care packages in the risk of adverse outcomes for mothers
and newborns [10]. The authors also stated that the wide-
spread application of the reduced visit package might, in
some settings, reduce cost.
In 2010, the Cochrane systematic review comparing
the effects of reduced visits, goal-oriented antenatal care
programs with the standard model of care for low-risk
women was updated [4]. This review included seven trials
of more than 60,000 women, four in high-income coun-
tries with individual randomization and three in low- and
middle-income countries with cluster randomization,
including the WHO ANC Trial. The four individually
randomized trials defined reduced frequency as six to
eight visits, whereas the three clusters randomized trials
used a reduced schedule of four to six visits. Primary out-
comes were maternal death, pre-eclampsia, perinatal
death, preterm birth and small for gestational age. The
reviewers found a borderline significant increase in peri-
natal mortality for women randomized to reduced visits
compared with standard care (RR 1.14; 95% CI 1.00, 1.31).
On sub-group analysis, the number of perinatal deaths in
the individually randomized trials was relatively low. How-
ever, the three cluster-randomized trials consistently
showed slightly higher perinatal mortality in the reduced
visits group (RR 1.15; 95% CI 1.01, 1.32).
WHO convened a technical consultation in November
2010 to discuss the implications of these findings and
released a statement [11]. The technical consultation
was unable to identify a specific cause for the increased
risk of perinatal mortality identified in the review. Pos-
sible factors discussed were differences in population,
baseline risk and gaps between visits in the second and
third trimester of pregnancy being too wide for timely
identification of fetal ill-health and appropriate responses,or simply a chance effect. The consultation recommended
that researchers from the three trials in question under-
take secondary analyses of their datasets to identify
possible causes. This secondary analysis of the WHO
ANC Trial data explores the relationship between the re-
duced visits antenatal care package and perinatal mortality.
Methods
The design of the WHO ANC Trial is described in detail
elsewhere [10,12]. In brief, antenatal clinics were
randomized to deliver the new antenatal care package or
the standard antenatal care protocol offered in accord-
ance with local guidelines. The new antenatal package
combined evidence-based screening, therapeutic inter-
ventions and maternal education across four antenatal
visits for low-risk women. A classifying form was used
by the clinics randomized to the new package to identify
any maternal medical and obstetric conditions and these
women received additional antenatal care appropriate to
that condition. The primary fetal/neonatal outcome was
low birth weight, the primary maternal outcome was a
maternal morbidity index defined as the presence of
at least one of the following: pre-eclampsia/eclampsia,
severe postpartum anemia and treated urinary tract in-
fections/pyelonephritis. Maternal and perinatal second-
ary outcomes included among others fetal and neonatal
mortality. The sample size calculations for the trial were
based solely on the primary outcomes, since the mortal-
ity end-points would have required a very large number
of participants [10].
A total of 53 clinics in Khon Kaen (Thailand), Havana
(Cuba), Jeddah (Saudi Arabia), and Rosario (Argentina)
were randomized. 12,568 women attended the 27 inter-
vention clinics for a median of five visits. 11,958 women
attended the 26 standard model clinics for a median of
eight visits. Rates of neonatal mortality (0.6% for the
new model vs. 0.7% for the standard model) were rela-
tively similar between groups, but the rates of overall
fetal death (1.4% for the new model vs. 1.1% for the
standard model) were not.
For this secondary analysis, only singleton births were
included. Women were stratified by baseline maternal
risk to determine if differences in maternal characteris-
tics between the intervention and control groups con-
tributed to the risk of perinatal mortality. Fetal death
was stratified by gestational age and compared between
intervention and control groups to explore differences in
risks according to timing of fetal death. We used gener-
alized linear modeling and robust variance Poisson
regression modeling (adjusted for clustering within
clinics) to determine relative risks for perinatal mortality
and fetal death by gestational age period. All analyses
were conducted using SAS software v9.2 (SAS Institute
Inc., Cary, NC, USA).
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In the WHO ANC Trial, 6,160 women were high risk
and 18,365 were low risk. Table 1 shows selected mater-
nal characteristics stratified by risk and by group. Low-
risk women were less likely to smoke and were younger
and more educated. Robust variance Poisson regression
modeling was used to compare perinatal outcomes be-
tween the new and standard model groups, adjusted for
maternal risk and other significant covariates from uni-
variate analysis. Table 2 shows that adjusted relative risk
of perinatal death is higher in the new model (Adjusted
RR 1.18; 95% CI 1.01, 1.37). This is due to an increased
relative risk of fetal death (Adjusted RR 1.27; 95% CI
1.03, 1.58), which can in turn be attributed to an





Married or stable union 2,981
Education less than primary 720 (
Smoking during pregnancy 493 (
Substance abuse 64 (
Ratio persons per room in house (mean, SD) 2.5
Maternal age in years (mean, SD) 26.8
Outcome of previous pregnancy
Abortion 887 (
Fetal death 87 (
Low birth weight (<2500 g) 374 (
Neonatal death 61 (
Hospital admission for hypertension or pre-eclampsia/eclampsia 215
Reproductive History
Any previous low birth weight baby 534 (
Any previous surgery of reproductive tract 227
Any previous abortion 1,443
Any previous fetal death or neonatal loss 563 (
Present pregnancy
Isoimmunization Rh -ve 143
Vaginal bleeding first trimester 445 (
Date of LMP unknown 208
Nulliparous 973 (
Primigravida 491 (
Maternal height in cm 157.2
Maternal weight at first visit in kg 61.4
Duration of gestation at first visit, in weeks 15.6
Late booking for antenatal care (>28 weeks) 368 ((Adjusted RR 1.64; 95% CI 1.27, 2.11). Crude and
adjusted relative risks were consistent for all outcomes.
Table 3 shows adjusted relative risks for fetal, neonatal
and perinatal mortality, stratified by maternal risk. Perinatal
mortality was not significantly different in high-risk
(Adjusted RR 0.94; 95% CI 0.79, 1.12) or low-risk
women (Adjusted RR 1.24; 95% CI 0.95, 1.63). Within
the high-risk group, the new model was associated with
an increase in the overall risk of fetal death (Adjusted
RR 1.78; 95% CI 1.33, 2.39) and an increased risk of
fetal death at less than 36 weeks (Adjusted RR 1.48;
95% CI 1.17, 1.89). In the low maternal risk group, the
new model was associated with an increase in the rela-
tive risk of fetal death at less than 36 weeks (Adjusted
RR 1.56; 95% CI 1.05, 2.31), however the overall risk ofby model of antenatal care
h-risk women N = 6,160 Low-risk women N = 18,365
odel Standard model New model Standard model
,287 N = 2,873 N = 9,281 N = 9,084
(90.8) 2,544 (89.1) 8,628 (93.0) 8.297 (91.4)
21.9) 591 (20.6) 1,484 (16.0) 1,291 (14.2)
15.0) 460 (16.0) 815 (8.8) 1,035 (11.4)
2.0) 41 (1.4) - -
(1.4) 2.4 (1.3) 2.4 (1.3) 2.4 (1.2)
(7.0) 26.7 (7.1) 25.1 (5.5) 24.7 (5.5)
27.0) 716 (24.9) 1,794 (19.3) 1,838 (20.2)
2.7) 68 (2.4) 5 (0.05) 6 (0.07)
11.4) 384 (13.4) - -
1.9) 45 (1.6) 5 (0.05) 2 (0.02)
(6.5) 132 (4.6) - -
16.3) 537 (18.7) 181 (2.0) 165 (1.8)
(6.9) 351 (12.2) - -
(50.4) 1,208 (48.9) 2,594 (36.8) 2,601 (38.8)
19.7) 464 (18.8) - -
(4.4) 76 (2.7) - -
13.5) 333 (11.6) - -
(6.3) 153 (5.3) 433 (4.7) 385 (4.2)
29.8) 903 (31.4) 2,739 (29.5) 2,755 (30.3)
14.9) 463 (16.1) 2,891 (30.4) 2,890 (31.8)
(6.8) 156.6 (6.6) 156.7 (5.5) 156.4 (6.5)
(13.7) 61.1 (13.2) 58.7 (12.1) 58.3 (11.8)
(8.0) 15.7 (7.8) 16.8 (8.6) 16.1 (8.0)
11.2) 294 (10.2) 1,285 (13.9) 1.052 (11.6)
Table 2 Crude and adjusted relative risks of perinatal outcomes






N (%) N (%)
Perinatal mortality 234/11672 (2.0) 190/11121 (1.7) 1.20 (1.04, 1.38) 1.18 (1.01, 1.37)*
Neonatal mortality 73/11511 (0.6) 71/11002 (0.7) 0.93 (0.80, 1.09) 0.95 (0.81, 1.11)
Fetal Death 161/11672 (1.4) 119/11121 (1.1) 1.30 (1.04, 1.62) 1.27 (1.03, 1.58)*
Fetal death <=36 weeks 122/11574 (1.1) 77/11048 (0.7) 1.63 (1.29, 2.08) 1.64 (1.27, 2.11)*
Fetal death >36 weeks 37/11574 (0.3) 42/11048 (0.4) 0.81 (0.52, 1.26) 0.78 (0.51, 1.21)
* RR estimates using robust variance Poisson modeling, taking clustering into account.
† Model adjusted for risk strata only.
‡ Multivariate model adjusted for risk strata, smoking, education less than primary, hospital admission in last pregnancy, previous surgery on reproductive tract,
late booking, vaginal bleeding in the first trimester, age, previous low birth weight, parity.
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1.26; 95% CI 0.91, 1.73). The risk of neonatal mortality
was not significantly different in low-risk women RR
1.35; 95% CI 0.87 – 2.10) but was significantly lower in
high-risk women (Adjusted RR 0.47; 95% CI 0.30, 0.72).
We tested baseline maternal risk as an effect modifier,
however this was not significant for any model (data
not shown).
Stratification of fetal deaths by gestational age (22 –
27, 28 – 31, 32 – 36 and >36 weeks) showed a statisti-
cally significant increase in fetal deaths between 32 to
36 weeks of gestation (Adj RR 2.24; 95% CI 1.42, 3.53),
the other periods were not significantly different be-
tween the comparison groups (Table 4). This pattern is
demonstrated in Figure 1, comparing hazard rates for
the reduced visits model and standard model.Table 3 Crude and adjusted relative risks of fetal and neonat
High maternal risk g
End points New model Standard model
N (%) N (%)
Perinatal mortality 91/2713 (3.35) 71/2412 (2.94)
Fetal death 65/2713 (2.40) 36/2412 (1.49)
Fetal death with GA <=36 weeks 51/2713 (1.9) 26/2412 (1.1)
Neonatal deaths 26/2648 (1.0) 35/2376 (1.5)
Low maternal risk g
End points New model Standard model
N (%) N (%)
Perinatal mortality 143/8959 (1.60) 119/8709 (1.37)
Fetal death 96/8959 (1.07) 83/8709 (0.95)
Fetal death with GA <=36 weeks 71/8959 (0.8) 51/8709 (0.6)
Neonatal deaths 47/8863 (0.5) 36/8626 (0.4)
* Relative risks adjusted for clustering within clinics.
0 Model adjusted for risk strata only.
† Model in high-risk women adjusted for risk strata, married or stable union, hospit
low birth weight and vaginal bleeding in the first trimester.
‡ Model in low-risk women adjusted for risk strata, married or stable union, smokin
previous abortion.Discussion
We conducted a secondary analysis of the WHO ANC
Trial dataset following the publication of a Cochrane
review that suggested the risk of perinatal mortality was
slightly higher in reduced-frequency, goal-oriented ante-
natal care packages for low-risk pregnancies in develop-
ing countries [4]. The analysis found that both high- and
low-risk women in the intervention group had an
increased relative risk of fetal death between 32 and 36 -
weeks gestation. While any association between ante-
natal care interventions and fetal death is cause for
concern, these findings are hypothesis-generating rather
than conclusive and must be interpreted with caution.
The Cochrane review included data from developed and
developing countries and the reviewers acknowledged that
there is considerable variation within and between theseal outcomes stratified by risk and model of antenatal care
roup (n = 5,125)
Crude relative risk (95% CI)*0 Adjusted relative risk (95% CI)*†
1.00 (0.85 – 1.17) 0.94 (0.79 – 1.12)
2.12 (1.53 - 2.94) 1.78 (1.33 – 2.39)
1.77 (1.48 – 2.10) 1.48 (1.17 – 1.89)
0.48 (0.31 – 0.72) 0.47 (0.30 – 0.72)
roup (n=17,668)
Crude relative risk (95% CI)*0 Adjusted relative risk (95% CI)*‡
1.14 (0.90, 1.44) 1.24 (0.95, 1.63)
1.18 (0.91 – 1.52) 1.26 (0.91 – 1.73)
1.48 (1.08 – 2.04) 1.56 (1.05 – 2.31)
1.38 (0.89 – 2.14) 1.35 (0.87 – 2.10)
al admission in last pregnancy, previous surgery on reproductive tract, previous
g, education less than primary, late booking, age, primigravidity and








N (%) N (%)
22 – 27 52/68 (76.5) 36/54 (66.7) 1.12 (0.98 – 1.29) 0.086
28 – 31 26/77 (33.8) 20/83 (24.1) 1.09 (0.78 – 1.51) 0.62
32 – 36 42/714 (5.9) 20/670 (3.0) 2.24 (1.42 – 3.53) 0.0005
> 36 37/10710 (0.4) 42/10237 (0.4) 0.81 (0.52 – 1.26) 0.35
† Model adjusted for risk strata only.
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[4]. While the increase in perinatal mortality in the three
cluster-randomized trials was a consistent finding, only
the pooled estimate reached borderline statistical signifi-
cance [4].
Women in these countries differed greatly in baseline
health risks and health resource availability, making com-
parisons problematic. Additionally, the 1996 Zimbabwe
trial and WHO ANC Trial were in mostly urban settings
[10,13], while the 2007 Zimbabwe trial was rural [14]. This
heterogeneity needs to be considered when interpreting the
marginal increase in perinatal mortality on pooled analysis.
Furthermore, data from the two Zimbabwean trials
showed that overall, women had similar numbers of
visits between intervention and controls groups,
suggesting that any increase in the risk of fetal death in
the intervention groups may be due to factors other
than the number of antenatal visits [13,14]. Secondary
analyses of the two Zimbabwean trials have not yet
been published.
In retrospect, the disparities in fetal mortality could
have been more thoroughly investigated and given
greater prominence in the published findings of the
WHO ANC Trial. One possible explanation for these
findings is that lower number of visits or other elements
of the new antenatal care package decrease the identifi-
cation of fetuses at risk of fetal death between 32 and
36 weeks. This may be attributable to prolonged gapsFigure 1 Fetal death hazard rate for gestational weeks 22 – 41.between antenatal visits (particularly between the second
and third trimester) or issues with the quality of ante-
natal care delivered. The number of antenatal visits can-
not necessarily act as a proxy for high quality care and
measuring the effective delivery of antenatal interven-
tions is difficult. Reducing the number of antenatal visits
may not necessarily translate into fewer visits of higher
quality for more women in low-resource settings. It may
also be that control clinics were providing other inter-
ventions that were of some benefit.
This analysis has several limitations. Control clinics in
the WHO ANC Trial used a regimen based on local
protocols; it is therefore likely that visit frequency dif-
fered both within and between control clinics. 47.6% of
women in the new model and 19.6% of women in the
standard model had fewer than five visits, rendering dif-
ferences in visit frequency negligible for this sub-group.
Cluster-randomized trials are an efficient study design
for trialing complex interventions in low-resource set-
tings, but it can be difficult to account for all potential
confounders that may differ between clusters. For
example, antenatal care providers in the WHO ANC
Trial were known to differ between study sites and
clinics, as well as rates of smoking, education, hospital
admission, previous gynecological surgery and late book-
ing for antenatal care [10]. Complete blinding in trials of
antenatal care is impossible, increasing the chance of a
selection or information bias emerging. However, it is
reassuring that after adjustment for identifiable, poten-
tial risk factors, the crude and adjusted results are simi-
lar. It is also worth noting that in high-risk women the
increased fetal mortality was accompanied by a statisti-
cally significant drop in neonatal mortality (Adjusted RR
0.47; 95% CI 0.30, 0.72). While the reasons for these
findings are unclear, it could be secondary to the higher
number of fetal deaths during pregnancy.
In many low-income countries, where resources are
limited, antenatal care coverage is poor and many
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such focusing on the provision of effective antenatal care
at a reduced frequency seems advantageous. On the
other hand, additional antenatal visits may serve to
reinforce maternal education and compliance, or provide
an opportunity for screening and treatment of a condi-
tion that had been missed, omitted or deteriorated since
the previous visit. The reduced visit model has been
adapted and implemented in the north-east region of
Thailand and is currently being scaled up to the whole
country. The model has been modified with an added visit
around 20 weeks for an ultrasound scan. Initial monitor-
ing of perinatal mortality has not revealed any adverse
outcomes in the north-east region. (P Lumbiganon, per-
sonal communication).
Conclusion
This secondary analysis of the WHO ANC Trial data
indicates there is an appreciable increased risk of fetal
death at 32 to 36 weeks gestation for women receiving
the goal-oriented, reduced frequency antenatal care
package. While it is plausible that this was due to re-
duced antenatal visits, differences in settings, popula-
tions or content and quality of care as well as the timing
of visits could also be playing a role; care must be taken
in comparing findings across varied settings, countries
and patient groups.
It is critical to monitor maternal, fetal and neonatal
indicators when implementing antenatal care protocols
in any setting. In settings where few women attend ante-
natal care, achieving four antenatal care visits with the
full complement of targeted, evidence-based interven-
tions at each visit is still meaningful. These programs
should be monitored not only in terms of number of
visits but also in terms of actual care delivered and
clinically meaningful maternal and perinatal outcomes.
Further research on rates of fetal death in centers using
reduced antenatal care packages would also be of
benefit.
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